PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS_Chinese Journal of Reparative and Reconstructive Surgery

Authors：

RENHui ¹ , SHENGengyang ¹ ,  JIANGXiaobing ² , LIANGDe ² , TANGJingjing ¹ , CUIJianchao ¹ , LINShunxin ¹ , ZHUANGHong ² , YANGZhidong ² , ZHANGShuncong ² , YAOZhensong ²

1. The First School of Clinic Medicine, Guangzhou University of Chinese Medicine, Guangzhou Guangdong, 510405, P. R. China;
2. Department of Spinal Surgery, the First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou Guangdong, 510405, P. R. China;

Corresponding?author：

JIANGXiaobing, Email: spinedrjxb@sina.com

Keywords：

Glucocorticoid-induced osteoporosis; Bone mass; N-terminal propeptide of type I procollagen; C-terminal cross-linking telopeptide of type I collagen; Estrogen; Rat

DOI：

10.7507/1002-1892.20150066

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To analyze the phasic changes of bone mass, bone turnover markers, and estrogen levels at different time points after glucocorticoid (GC) intervention in rat and their correlation. Methods Thirty-four female 3-month-old Sprague Dawley rats were randomly divided into the following 3 groups:baseline group (n=6), dexamethasone (DXM) group (n=14), and control group (n=14). Rats were injected with DXM at the dose of 0.75 mg/kg, twice a week for 12 weeks in DXM group, with salt solution lavage in control group, and no treatment was given in baseline group. The body mass, adrenal weight, and uterus weight were measured. Bone mineral density (BMD), bone mineral content (BMC), and bone area (BA) of lumbar vertebral and femurs were detected by dual energy X-ray absorptiometry. Meanwhile, the serum levels of N-terminal propeptide of type I procollagen (PINP), C-terminal cross-linking telopeptide of type I collagen (β-CTX), and estrogen levels were determined by ELISA before experiment in baseline group and at 4, 8, and 12 weeks after experiment in control and DXM groups. At last, the correlation was analyzed among body weight, BMD, PINP, β-CTX, estrogen levels, and GC intervention duration of DXM group. Results The body mass, adrenal weight, and uterus weight in DXM group were significantly lower than those in baseline group and control group at all the time points (P<0.05). The levels of PINP and β-CTX elevated slowly in DXM group, significant difference was found at 12 weeks (P<0.05), but no significant difference at the 4 and 8 weeks (P>0.05) when compared with those in baseline group and control group. The estrogen level in DXM group was significantly lower than that in baseline group and control group at all the time points (P<0.05). BMD, BMC, and BA of lumbar vertebral and femurs in DXM group were significantly lower than those in control group at all the time points after GC intervention (P<0.05). Loss of bone mass of L₂ and femoral trochanteric region in DXM group was the lowest of all ranges of interest (ROIs). BMC and BA of lumbar vertebrae and BA of femoral shaft in DXM group at 4 weeks were significantly lower than those in baseline group (P<0.05). But there was no significant difference in BMD, BMC, and BA of other lumbar vertebrae and femurs' ROIs between DXM group and baseline group at all the time points (P>0.05). After GC intervention, BMD of lumbar vertebrae and femurs had negative correlation with PINP and β-CTX (P<0.05) and positive correlation with estrogen level (P<0.05). Conclusion The bone mass decreases rapidly at the early stage after GC intervention and then maintains a low level with time, the levels of bone turnover markers show a progressive increase, and the estrogen levels show a decrease trend. In addition, body weight, the levels of bone turnover markers and estrogen are associated with the change of bone mass.

Citation： RENHui, SHENGengyang, JIANGXiaobing, LIANGDe, TANGJingjing, CUIJianchao, LINShunxin, ZHUANGHong, YANGZhidong, ZHANGShuncong, YAOZhensong. PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS. Chinese Journal of Reparative and Reconstructive Surgery, 2015, 29(3): 307-314. doi: 10.7507/1002-1892.20150066 Copy

1.	Overman RA, Gourlay ML, Deal CL, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporosis International, 2015.[Epub ahead of print].
2.	Briota K, Cortetb B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine, 2014, 81(6):493-501.
3.	den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep, 2011, 13(3):233-240.
4.	田麗花, 梁敏, 張劼, 等. 糖皮質激素性骨質疏松大鼠模型建立的研究. 廣西醫科大學學報, 2013, 30(1):5-7.
5.	Pasqualetti S, Congiu T, Banfi G, et al. Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale. Int J Exp Pathol, 2015.[Epub ahead of print].
6.	Hulley PA, Conradie MM, Langeveldt CR, et al. Glucocorticoid-induced osteoporosis in the rat is prevented by tyrosine phosphatase inhibitor, sodium orthovanadate. Bone, 2002, 31(1):220-229.
7.	Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid induced bone loss with alendronate. Proc Soc Exp Biol Med, 1998, 217(2):162-167.
8.	Kim HK, Kim MG, Leem KH. Osteogenic activity of collagen peptide via ERK/MAPK pathway mediated boosting of collagen synthesis and its therapeutic efficacy in osteoporotic bone by back-scattered electron imaging and microarchitecture analysis. Molecules, 2013, 18(12):15474-15489.
9.	Ma B, Zhang Q, Wu D, et al. Strontium fructose 1, 6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin, 2012, 33(4):479-89.
10.	周樂, 吳鐵, 崔燎. 淫羊藿調節BMP-7預防糖皮質激素致大鼠骨損害的研究. 中國骨質疏松雜志, 2014, 20(3):234-237, 241.
11.	陳婷穎, 任偉. 成人生長激素缺乏癥與骨質疏松. 現代醫藥衛生, 2014, 30(13):1965-1967.
12.	Lin S, Huang J, Zheng L, et al. Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int, 2014, 95(4):362-373.
13.	戴哲浩, 康意軍, 呂國華, 等. 糖皮質激素對成年大鼠骨量的影響. 中國骨質疏松雜志, 2014, 20(4):366-371.
14.	柯務. 體重指數與男性骨質疏松關系的研究. 中國現代醫生, 2013, 51(21):25-26.
15.	Hamidi MS, Corey PN, Cheung AM. Effects of vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res, 2012, 27(6):1368-1380.
16.	Sbrocchi AM, Rauch F, Matzinger M, et al. Vertibral fractures despite normal spine bone mineral density in a boy with nephritic syndrome. Pediatr Nephrol, 2011, 26(1):139-142.
17.	Li M, Li Y, Deng W, et al. Chinese bone turnover marker study:reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal Peptide by age and gender. PLoS One, 2014, 9(8):e103841.
18.	歐萌萌, 黃建榮. 絕經后婦女骨質疏松癥患者血清β-Crosslaps、PINP和N-MID檢測的評價. 標記免疫分析與臨床, 2011, 18(4):238-240.
19.	Farahmand P, Marin F, Hawkins F, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int, 2013, 24(12):2971-2981.
20.	劉曉紅, 盧文, 錢浩, 等. 糖皮質激素對腎小球疾病患者骨密度和骨轉換指標的影響. 實用醫學雜志, 2014, 30(22):3583-3586.
21.	McManus MM, Grill RJ. Longitudinal evaluation of mouse hind limb bone loss after spinal cord injury using novel, in vivo, methodology. J Vis Exp, 2011, (58):e3246.

1. Overman RA, Gourlay ML, Deal CL, et al. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporosis International, 2015.[Epub ahead of print].
2. Briota K, Cortetb B, Roux C, et al. 2014 update of recommendations on the prevention and treatment of glucocorticoid-induced osteoporosis. Joint Bone Spine, 2014, 81(6):493-501.
3. den Uyl D, Bultink IE, Lems WF. Advances in glucocorticoid-induced osteoporosis. Curr Rheumatol Rep, 2011, 13(3):233-240.
4. 田麗花, 梁敏, 張劼, 等. 糖皮質激素性骨質疏松大鼠模型建立的研究. 廣西醫科大學學報, 2013, 30(1):5-7.
5. Pasqualetti S, Congiu T, Banfi G, et al. Alendronate rescued osteoporotic phenotype in a model of glucocorticoid-induced osteoporosis in adult zebrafish scale. Int J Exp Pathol, 2015.[Epub ahead of print].
6. Hulley PA, Conradie MM, Langeveldt CR, et al. Glucocorticoid-induced osteoporosis in the rat is prevented by tyrosine phosphatase inhibitor, sodium orthovanadate. Bone, 2002, 31(1):220-229.
7. Wimalawansa SJ, Simmons DJ. Prevention of corticosteroid induced bone loss with alendronate. Proc Soc Exp Biol Med, 1998, 217(2):162-167.
8. Kim HK, Kim MG, Leem KH. Osteogenic activity of collagen peptide via ERK/MAPK pathway mediated boosting of collagen synthesis and its therapeutic efficacy in osteoporotic bone by back-scattered electron imaging and microarchitecture analysis. Molecules, 2013, 18(12):15474-15489.
9. Ma B, Zhang Q, Wu D, et al. Strontium fructose 1, 6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway. Acta Pharmacol Sin, 2012, 33(4):479-89.
10. 周樂, 吳鐵, 崔燎. 淫羊藿調節BMP-7預防糖皮質激素致大鼠骨損害的研究. 中國骨質疏松雜志, 2014, 20(3):234-237, 241.
11. 陳婷穎, 任偉. 成人生長激素缺乏癥與骨質疏松. 現代醫藥衛生, 2014, 30(13):1965-1967.
12. Lin S, Huang J, Zheng L, et al. Glucocorticoid-induced osteoporosis in growing rats. Calcif Tissue Int, 2014, 95(4):362-373.
13. 戴哲浩, 康意軍, 呂國華, 等. 糖皮質激素對成年大鼠骨量的影響. 中國骨質疏松雜志, 2014, 20(4):366-371.
14. 柯務. 體重指數與男性骨質疏松關系的研究. 中國現代醫生, 2013, 51(21):25-26.
15. Hamidi MS, Corey PN, Cheung AM. Effects of vitamin E on bone turnover markers among US postmenopausal women. J Bone Miner Res, 2012, 27(6):1368-1380.
16. Sbrocchi AM, Rauch F, Matzinger M, et al. Vertibral fractures despite normal spine bone mineral density in a boy with nephritic syndrome. Pediatr Nephrol, 2011, 26(1):139-142.
17. Li M, Li Y, Deng W, et al. Chinese bone turnover marker study:reference ranges for C-terminal telopeptide of type I collagen and procollagen I N-terminal Peptide by age and gender. PLoS One, 2014, 9(8):e103841.
18. 歐萌萌, 黃建榮. 絕經后婦女骨質疏松癥患者血清β-Crosslaps、PINP和N-MID檢測的評價. 標記免疫分析與臨床, 2011, 18(4):238-240.
19. Farahmand P, Marin F, Hawkins F, et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos Int, 2013, 24(12):2971-2981.
20. 劉曉紅, 盧文, 錢浩, 等. 糖皮質激素對腎小球疾病患者骨密度和骨轉換指標的影響. 實用醫學雜志, 2014, 30(22):3583-3586.
21. McManus MM, Grill RJ. Longitudinal evaluation of mouse hind limb bone loss after spinal cord injury using novel, in vivo, methodology. J Vis Exp, 2011, (58):e3246.

Chinese Journal of Reparative and Reconstructive Surgery

PHASIC CHANGES OF BONE MASS, BONE TURNOVER MARKERS, AND ESTROGEN LEVELS AT DIFFERENT TIME POINTS AFTER GLUCOCORTICOID INTERVENTION AND THEIR CORRELATION IN RATS

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content